NovaBridge Biosciences
NBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $4,486 | -$10,697 | $88,026 |
| % Growth | -100% | 141.9% | -112.2% | – |
| Cost of Goods Sold | $0 | $0 | $27,237 | $46,432 |
| Gross Profit | $0 | $4,486 | -$248,800 | $41,594 |
| % Margin | – | 100% | 2,325.8% | 47.3% |
| R&D Expenses | $158,899 | $114,359 | $155,506 | $190,295 |
| G&A Expenses | $216,459 | $63,908 | $815,766 | $899,943 |
| SG&A Expenses | $216,459 | $63,908 | $199,875 | $899,943 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $337,381 | -$0 | $1,022,662 |
| Operating Expenses | $375,358 | $515,648 | $355,381 | $2,112,900 |
| Operating Income | -$375,358 | -$511,162 | -$366,078 | -$2,071,307 |
| % Margin | – | -11,395.1% | 3,422.2% | -2,353.1% |
| Other Income/Exp. Net | $12,627 | -$954,532 | -$607,088 | -$260,729 |
| Pre-Tax Income | -$362,731 | -$1,465,694 | -$973,166 | -$2,332,036 |
| Tax Expense | $0 | -$1,258,926 | $697 | -$495 |
| Net Income | -$162,257 | -$1,465,694 | -$2,507,317 | -$2,331,541 |
| % Margin | – | -32,674% | 23,438.9% | -2,648.7% |
| EPS | -4.46 | -17.62 | -30.38 | -30.7 |
| % Growth | 74.7% | 42% | 1% | – |
| EPS Diluted | -4.46 | -17.62 | -30.38 | -30.68 |
| Weighted Avg Shares Out | 81,186 | 83,193 | 82,516 | 75,934 |
| Weighted Avg Shares Out Dil | 81,186 | 83,228 | 82,516 | 75,960 |
| Supplemental Information | – | – | – | – |
| Interest Income | $54,640 | $7,300 | $4,954 | $21,333 |
| Interest Expense | $0 | $102 | $0 | $0 |
| Depreciation & Amortization | $1,905 | $3,371 | $1,415 | $13,776 |
| EBITDA | -$373,453 | -$344,250 | -$51,230 | -$2,057,531 |
| % Margin | – | -7,674.2% | 478.9% | -2,337.4% |